Clene (CLNN)
(Delayed Data from NSDQ)
$0.33 USD
-0.01 (-3.58%)
Updated May 31, 2024 04:00 PM ET
After-Market: $0.33 0.00 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLNN 0.33 -0.01(-3.58%)
Will CLNN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CLNN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLNN
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
CLNN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates
Dentsply International (XRAY) Q4 Earnings and Revenues Beat Estimates
Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates
Other News for CLNN
Clene Shareholders Approve Expansion and Governance Changes
Wall Street Analysts Are Bullish on Top Healthcare Picks
Analysts Are Bullish on These Healthcare Stocks: Allakos (ALLK), Clene (CLNN)
Analysts Offer Insights on Healthcare Companies: Allakos (ALLK), Calliditas Therapeutics (CALT) and Clene (CLNN)
Analysts Offer Insights on Healthcare Companies: Clene (CLNN) and Allakos (ALLK)